In recent years, significant progress has been made in both optical imaging systems and fluorescent contrast agents for clinical applications. NIRF imaging with a free-floating imaging device mounted on the ceiling of the operating theatre or on a microscope articulating arm during surgery for cancer will enable visualization of tumor delineation, locoregional metastases, remnant disease as well as e.g. tumor-containing lymph nodes. Hereby, the surgeon can both detect (diagnostic) and excise (therapeutic) malignant tissue and possible residual disease at the same time. The use of NIRF optical imaging has a range of advantages. Most prominent among these is the fact that it is very safe technology, simple to operate, fast, high resolution (as low as 1 mm), relatively inexpensive and makes use of non-ionizing radiation. Based on the above, it is clear that intra-operative imaging is on the verge of entering standard clinical practice for surgery. Not only the imaging system but also the availability of clinical grade tumor-targeted probes is of the utmost importance for a successful introduction into clinical practice. This talk will give an overview of the current concepts and future perspectives of intraoperative fluorescence image-guided surgery using non-targeted and targeted optical contrast agents for the first-time ever used in patients with ovarian cancer and the anticipated developments within the next 5 years. It will become clear that agencies like the FDA and EMA will play a major role in bringing this technology into the clinic and the necessity of standardization of methodology when applied in multinational multicenter studies. Moreover, the role of optical molecular imaging as a screening instrument in preventive medicine will be outlined.
Citation Format: Gooitzen M. van Dam. Expediting clinical translation of optical molecular imaging techniques in oncology and its role in preventive medicine. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr CN08-01.
- ©2013 American Association for Cancer Research.